Efficacy and Safety of ARI0002H (BCMA-Directed CAR T) in RRMM Patients Presented at EHA 2022

Dr. Carlos Fernandez de Larrea Discusses Efficacy and Safety of BCMA-Directed CAR T-Cell Therapy (ARI0002H) in RRMM Patients

Abstract Title:

Efficacy and Safety of ARI0002H, an Academic BCMA-Directed CAR T-cell Therapy with Fractionated Initial Therapy and Booster Dose in Patients with Relapsed/Refractory Multiple Myeloma

What is the purpose of this trial? 

To assess the safety and efficacy of CAR T BCMA ARI0002h in patients with relapsed/refractory multiple myeloma (RRMM) who have received treatment with proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody. (From NCT04309981)

ARI0002h is a lentiviral autologous CAR T-cell product with a 4-1BB co-stimulatory domain and a humanized single chain variable fragment targeting BCMA. In pre-clinical studies, this academic CAR-T has demonstrated potent in vitro and in vivo activity. 

Safety and efficacy results of the CARTBCMA-HCB-01 multicenter clinical trial for patients with relapsed/refractory multiple myeloma (RRMM), who received ARI0002h in 5 Spanish centers, are reported here. 

In this video:

Dr. Carlos Fernandez de Larrea (Department of Hematology, Amyloidosis and Myeloma Unit, Hospital Clínic de Barcelona—Barcelona, Spain) discusses the efficacy and safety of BCMA-Directed CAR T-cell Therapy (ARI0002H) in RRMM patients who received treatment in 5 Spanish centers. 

Conclusion:

The first European academic CAR T for relapsed/refractory multiple myeloma (RRMM), ARI0002h has demonstrated deep and durable responses and a favorable safety profile, including the absence of neurotoxicity and the feasibility of a second booster dose.

Clinical trial information: NCT04309981